Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2019-03-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation & Information Statement' (PSI) filed by (주)지트리비앤티 (GtreeBNT). It contains details regarding the solicitation of proxies for an upcoming Annual General Meeting (AGM), including the date, location, purpose of the meeting (approval of financial statements), and detailed financial statements (balance sheets, income statements, cash flow statements) for the fiscal year 2018. The document structure follows the standard Korean regulatory format for proxy solicitation materials (참고서류).
2019-03-11 Korean
증권발행결과(자율공시)(제8회차 CB)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Issuance Result' (증권 발행결과) for a convertible bond (CB) issuance. It details the final issuance amount, payment date, and the nature of the securities. This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments (convertible bonds).
2019-03-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (DART system) to report changes in shareholdings by insiders or major shareholders. Since the document details a change in share ownership (a decrease of 35,211 shares) by a major shareholder (Yuyang D&U), it falls under the category of 'Director's Dealing' (DIRS), which covers insider/major shareholder transactions.
2019-03-06 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically due to exchangeable bond conversion) by a major shareholder (Yuyang D&U) in the company 'GtreeBNT'. This falls under the category of Major Shareholding Notification.
2019-03-06 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korea Exchange regarding the decision to issue convertible bonds (전환사채권 발행결정). It details the terms of the issuance, including interest rates, conversion prices, put options, and the list of investors. This type of filing is a standard regulatory disclosure for capital structure changes and financing activities in the Korean market, which falls under the 'Capital/Financing Update' category.
2019-03-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often filed via DART) to report changes in shareholdings by insiders or major shareholders. Based on the provided categories, this fits the definition of a 'Major Shareholding Notification' (MRQ) as it details the change in ownership percentage of a major shareholder (Yuyang D&U) in the issuing company (HLB Therapeutics/GtreeBNT).
2019-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.